Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Publications IgAN

Sparsentan is superior to losartan in the gddY mouse model 1 of IgA nephropathy

View
Medical Information FSGS

FILSPARI (sparsentan): Changes in Blood Pressure and Hypotensive Events in FSGS

Learn more
Medical Information FSGS

FILSPARI (sparsentan): Effect on Estimated Glomerular Filtration Rate (eGFR) in FSGS

Learn more
Medical Information FSGS

FILSPARI (sparsentan): Dosing and Administration in Clinical Trials of FSGS

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 PROTECT Study Published in The Lancet

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 DUPLEX Study Published in the NEJM

Learn more
Publications FSGS

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

View
Abstracts IgAN

Sparsentan receptor occupancy modeling, clinical actions, and safety

View
Abstracts IgAN

Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial

View
Posters

Long-Term Efficacy and Safety of Sparsentan in Young Patients With FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)

Learn More
Abstracts IgAN

Sparsetan Reduces Proteinuria in Patients with Immunoglobulin A Nephropathy (IgAN): Interim Results of the PROTECT Study

View
Abstracts IgAN

Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases

View
Abstracts IgAN

Sparsentan receptor occupancy modeling, clinical actions, and safety

View